Bayer Moves Anti-Thrombotic Into Phase III For Two Indications
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer is set to begin Phase III trials for its antithrombotic agent BAY 59-7939 for a general venous thromboembolism indication following promising Phase II results, the company announced June 12
You may also be interested in...
Coulda, Shoulda? Sanofi's Skip On Portola Proves Clot-Buster Gain For Novartis
Deal could complicate venture investors' exit, though Portola thinks not – as another would-be partner eyes second lead product.
Coulda, Shoulda? Sanofi's Skip On Portola Proves Clot-Buster Gain For Novartis
Deal could complicate venture investors' exit, though Portola thinks not – as another would-be partner eyes second lead product.
Bayer/J&J Plan Rivaroxaban Filing For Chronic Indications In 2010
An earlier filing for the oral factor Xa inhibitor is planned in the U.S. in 2008 for the prevention of venous thromboembolism.